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Background: MYC deregulation is a common event in gastric carcinogenesis, usually as a consequence of gene
amplification, chromosomal translocations, or posttranslational mechanisms. FBXW7 is a p53-controlled tumor-suppressor
that plays a role in the regulation of cell cycle exit and reentry via MYC degradation.
Methods: We evaluated MYC, FBXW7, and TP53 copy number, mRNA levels, and protein expression in gastric cancer and
paired non-neoplastic specimens from 33 patients and also in gastric adenocarcinoma cell lines. We also determined the
invasion potential of the gastric cancer cell lines.
Results: MYC amplification was observed in 51.5% of gastric tumor samples. Deletion of one copy of FBXW7 and TP53
was observed in 45.5% and 21.2% of gastric tumors, respectively. MYC mRNA expression was significantly higher in
tumors than in non-neoplastic samples. FBXW7 and TP53 mRNA expression was markedly lower in tumors than in paired
non-neoplastic specimens. Moreover, deregulated MYC and FBXW7 mRNA expression was associated with the presence
of lymph node metastasis and tumor stage III-IV. Additionally, MYC immunostaining was more frequently observed in
intestinal-type than diffuse-type gastric cancers and was associated with MYC mRNA expression. In vitro studies showed
that increased MYC and reduced FBXW7 expression is associated with a more invasive phenotype in gastric cancer cell
lines. This result encouraged us to investigate the activity of the gelatinases MMP-2 and MMP-9 in both cell lines. Both
gelatinases are synthesized predominantly by stromal cells rather than cancer cells, and it has been proposed that both
contribute to cancer progression. We observed a significant increase in MMP-9 activity in ACP02 compared with ACP03
cells. These results confirmed that ACP02 cells have greater invasion capability than ACP03 cells.
Conclusion: In conclusion, FBXW7 and MYC mRNA may play a role in aggressive biologic behavior of gastric cancer
cells and may be a useful indicator of poor prognosis. Furthermore, MYC is a candidate target for new therapies against
gastric cancer.
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Gastric cancer (GC) is the fourth most common can-
cer and the second leading cause of cancer death
worldwide [1]. GC is considered a major public health
concern, especially in developing countries, including
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reproduction in any medium, provided the orA fundamental aspect of carcinogenesis is uncon-
trolled cell proliferation resulting from the accumulation
of changes that promote the expression or repression of
cell cycle-control genes [3]. MYC is a transcriptional
factor involved in cell cycle regulation and cell growth
arrest that is commonly deregulated in cancers and has
been described as a key element of gastric carcinogenesis
[4,5]. Several different types of posttranslational modifi-
cations of MYC have been described, including phos-
phorylation, acetylation, and ubiquitination [6]. The
ubiquitin-proteasome system is the major protein degrad-
ation regulatory pathway involved in cell differentiational Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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subunit of the Skp1/Cul1/F-box complex (SCF) ubiquitin
ligase complex. SCFFBXW7 induces degradation of the
products of positive cell cycle regulator genes, such as cyclin
E, MYC, NOTCH, and JUN, through phosphorylation-
dependent ubiquitination [8]. Among SCFFBXW7 substrates,
MYC is of particular importance in cell cycle exit because
it is thought to play a role in determining whether mam-
malian cells divide or not [9].
Deregulated FBXW7 expression is a major cause of
carcinogenesis [10-12]. Loss of FBXW7 expression can
lead to MYC overexpression and has been associated
with poor prognosis in GC patients [13]. However, MYC
activation by FBXW7 loss triggers activation of p53,
which plays a key role in the regulation of cellular
responses to DNA damage and abnormal expression of
oncogenes. Induction of cell cycle arrest by p53 allows
for DNA repair or apoptosis induction [14]. Thus,
concomitant loss of FBXW7 and TP53 is necessary to
induce genetic instability and tumorigenesis [11].
In the present study, we investigated MYC, FBXW7,
and TP53 gene copy number variation and mRNA and
protein expression in GC samples and gastric adenocar-
cinoma cell lines. Possible associations between our
findings and the clinicopathological features and/or
invasion and migration capability of the cell lines were
also evaluated.Methods
Clinical samples
Samples were obtained from 33 GC patients who under-
went surgical treatment at the João de Barros Barreto
University Hospital in Pará State, Brazil. Dissected
tumor and paired non-neoplastic tissue specimens were
immediately cut from the stomach and frozen in liquid
nitrogen until RNA extraction.
The clinicopathological features of the patient samples
are shown in Table 1. GC samples were classified
according to Lauren [15]. All GC samples showed the
presence of Helicobacter pylori, and the cagA virulence
factor was determined by PCR analysis of ureA and cagA
as described by Clayton et al. [16] and Covacci et al.
[17], respectively. All patients had negative histories of
exposure to either chemotherapy or radiotherapy before
surgery, and there were no other co-occurrences of diag-
nosed cancers. Informed consent with approval of the
ethics committee of the Federal University of Pará was
obtained.Cells lines
Gastric adenocarcinoma cell lines ACP02 and ACP03
[18] were cultured in complete RPMI medium (Invitrogen
Corp., Carlsbad, CA, USA) supplemented with 10% fetalbovine serum (FBS), 1% penicillin/streptomycin, and 1%
kanamycin.
Copy number variation (CNV)
DNA was extracted using a DNAQiamp mini kit (Qiagen,
Hilden, Germany) according to the manufacturer’s
instructions. Duplex quantitative real-time PCR (real-time
qPCR) was performed using the FAM/MGB-labeled
TaqMan probes for MYC (Hs01764918_cn), FBXW7
(Hs01362464_cn), or TP53 (Hs06423639_cn), and VIC/
TAMRA-labeled TaqMan CNV RNAse P (#4403326) was
used for the internal control. All real-time qPCR reactions
were performed in quadruplicate with gDNA according to
the manufacturer’s protocol using a 7500 Fast Real-Time
PCR system (Life Technologies, Foster City, CA, USA).
The copy number of each sample was estimated by CNV
analysis using Copy Caller Software V1.0 (Life Technologies,
Foster City, CA, USA). Known Human Genomic DNA
(Promega, Madison, USA) was used for calibration.
Quantitative real-time reverse transcriptase PCR
Total RNA was extracted with TRI Reagent® Solution
(Life Technologies, Carlbad, CA, USA) following the
manufacturer’s instructions. RNA concentration and
quality were determined using a NanoDrop spectropho-
tometer (Thermo Scientific, Wilmington, DE, USA) and
1% agarose gels. Complementary DNA (cDNA) was
synthesized using a High-Capacity cDNA Archive kit
according to the manufacturer’s recommendations
(Life Technologies, Foster City, CA, USA). Real-time
qPCR primers and TaqMan probes targeting MYC
(Hs00153408_m1), FBXW7 (Hs00217794_m1), and TP53
(Hs01034249_m1) were purchased as Assays-on-Demand
Products for Gene Expression ((Life Technologies, Foster
City, CA, USA). Real time qPCR was performed using an
ABI Prism 7500 system (Life Technologies, Foster City,
CA, USA) according to the manufacturer’s instructions.
GAPDH (NM_002046.3; Life Technology, USA) was
selected as an internal control for monitoring RNA input
and reverse transcription efficiency. All real-time qPCR
reactions for target genes and internal controls were
performed in triplicate on the same plate. The relative
quantification (RQ) of gene expression was calculated
using the ΔΔCt method [19], in which the non-neoplastic
sample was designated as a calibrator for each paired
tumor sample.
Immunohistochemistry
Immunohistochemical analyses for MYC and p53 were
performed on formalin-fixed, paraffin-embedded surgical
sections. Serial 3-μm sections were used. Heat-induced
antigen retrieval was employed (microprocessor-controlled
pressure Pascal® DakoCytomation, Carpinteria, CA, USA).
A universal peroxidase-conjugated secondary antibody kit
Table 1 MYC, FBXW7 and TP53 gene copy number variation, MYC and p53 protein expression and clinicopathological features of 33 GC patients
CNV MYC CNV FBXW7 CNV TP53 IHC MYC IHC p53
2 copies
(n = 16)
≥ 3 copies
(n = 17)
p- value 2 copies
(n = 18)
1 copy
(n = 15)
p- value 2 copies
(n = 25)
1 copy
(n = 7)
p- value P (n = 19) N (n = 14) p- value P (n = 6) N (n = 25) p- value
Age (y) (mean ± SD)
>50 (65.3 ± 9.1) 7 12 0.166 12 7 0.304 15 3 0.393 10 4 0.310 5 9 0.094
≤50 (42.1 ± 8.2) 9 5 6 8 10 4 10 9 2 17
Gender
Male 8 7 0.437 7 8 1.000 13 1 0.104 12 3 0.072 2 13 0.413
Female 8 10 8 10 12 6 8 10 5 13
Histopathology
Intestinal 12 10 0.465 12 10 1.000 16 6 0.387 17 5 0.009* 6 16 0.378
Diffuse 4 7 6 5 9 1 3 8 1 10
Depth of tumor invasion
T1 3 3 1.000 5 1 0.186 5 1 1.000 2 4 0.182 1 5 1.000
T2-T4 13 14 13 14 20 6 18 9 6 21
Lymph node metastasis
Absent 5 8 0.481 8 5 0.722 10 3 1.000 7 6 0.717 2 11 0.676
Present 11 9 10 10 15 4 13 7 5 15
Stage
I-II 8 10 0.732 12 6 0.170 14 3 0.678 12 6 0.493 3 15 0.674
III-IV 8 7 6 9 11 4 8 7 4 11
MYC IHC
Negative 5 8 0.481 7 6 1.000 11 2 0.671
Positive 11 9 11 9 14 5
p53 IHC
Negative 14 12 0.398 14 12 1.000 21 4 0.157
Positive 2 5 4 3 4 3
*p < 0.05; P: positive; N: negative.
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was used for detection with diaminobenzidine (DAB) as
the chromogen. The following primary antibodies were
used: mouse monoclonal antibodies directed against MYC
(dilution 1:150; sc-40, Santa Cruz Biotechnology, Santa
Cruz, CA, USA and clone 9E10, Zymed®, San Francisco,
CA, USA), FBXW7 (dilution 1:50, Abnova Corp., Taipei
City, Taiwan), and p53 (dilution 1:50; DakoCytomation,
Carpinteria, CA, USA). Positive protein expression was
defined as clear nuclear staining in more than 10% of the
cells.
Migration and invasion assay
Migration and invasion assays were carried out in a
modified Boyden chamber with filter inserts (8-μm
pores) for 12-well plates (BD Biosciences, San Jose, CA,
USA). To assess invasion, filters were coated with 10 μl
of Matrigel (10–13 mg/ml) (BD Biosciences, San Jose,
CA, USA) while on ice. Cells (2 × 105) were plated into
the upper chamber in 1 ml of RPMI without FBS. The
lower chamber was filled with 1.5 ml of RPMI with FBS.
After 48 h in culture, cells were fixed with 4% parafor-
maldehyde and post-fixed with 0.2% crystal violet in 20%
methanol. Cells on the upper side of the filter, including
those in the Matrigel, were removed with a cotton swab.
Invading cells (on the lower side of the filter) were
photographed and counted. Experiments were performed
in triplicate.
Immunofluorescence
Cells grown on glass coverslips were fixed with 1% para-
formaldehyde in phosphate-buffered saline (PBS) for
10 min, then permeabilized with 0.5% Triton X-100
(Sigma-Aldrich, St. Louis, MO, USA) in PBS for 15 min
and blocked with 1% bovine serum albumin (BSA) in
PBS. The cells were stained with mouse antibodies
against MYC (diluted 1:50; Zymed®, USA), p53 (diluted
1:50; DakoCytomation, Carpinteria, CA, USA), and
FBXW7 (diluted 1:50; Abnova Corp., Taipei City,
Taiwan). Primary antibodies were revealed using an anti-
mouse Alexa-568-conjugated secondary antibody
(Invitrogen). All incubations were carried out for 60 min
at room temperature. Nuclei were stained with DAPI in
Prolong anti-fade mounting medium (Invitrogen).
Negative control samples were processed as described
above except that primary antibodies were omitted and
replaced with PBS alone.
Western blotting
Protein extraction from cells was performed according
to standard procedures. Briefly, total protein was extracted
from ACP02 and ACP03 cells using 50 mM Tris–HCl
buffer containing 100 mmol/L NaCl, 50 mM NaF, 1 mM
NaVO4, 0.5% NP-40, and complete protease inhibitorcocktail (Roche, Germany). Protein concentration was
estimated using a Bradford assay (Sigma-Aldrich). About
30 μg of total protein extract was loaded onto a 12%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) gel and electrophoresed. Resolved proteins
were then transferred from the gel onto a nitrocellulose
membrane. The membrane was blocked with 5% nonfat
milk in Tris-buffered saline containing 5% Tween (Sigma-
Aldrich, Sant Louis, MO, USA) and then incubated with
mouse monoclonal anti-MYC (Santa Cruz Biotechnology),
anti-FBXW7 (Abnova, Taipei City, Taiwan), anti-p53
(DakoCytomation, Carpinteria, CA, USA), and anti-β-
actin (Sigma-Aldrich, Sant Louis, MO, USA) antibodies
diluted 1:200, 1:100, 1:100, and 1:2,000, respectively.
Subsequently, membranes were incubated with a 1:5,000
dilution of horseradish peroxidase (HRP)-conjugated
sheep anti-mouse antibody (Amersham Biosciences,
Piscataway, NJ, USA) for 1 h at room temperature.
Proteins were visualized by enhanced chemiluminescence.
Zymography
ACP02 and ACP03 cells (5 × 104 of each) were plated
and allowed to adhere and spread for at least 8 h. Adher-
ent cells were washed three times with PBS, and the
culture medium was replaced with serum-free medium
for 24 h. The activity of MMP2 and MMP9 in the condi-
tioned medium was assessed by zymography. Condi-
tioned medium was collected, concentrated (Microcon
30 K, Merck Millipore, Darmstadt, Germany) and
resuspended in SDS-PAGE sample buffer (without β-
mercaptoethanol). The remaining cells were lysed and
the protein concentration was estimated using a BCA
assay (Thermo Scientific Pierce, Rockford, IL, USA). A
total of 1 μg of protein from each conditioned medium
was separated on 10% polyacrylamide gels containing
0.2% gelatin. After electrophoresis, the gels were washed
in 2.5% Triton X-100 for 30 min, then equilibrated in
10 mM Tris (pH 8.0) and incubated at 37°C for 16–24 h
in a development buffer containing 50 mM Tris
(pH 8.0), 5 mM CaCl2, and 0.02% NaN3. The gels were
stained with 0.2% Coomassie blue R250 (GE Amersham,
Piscataway, NJ, USA) and destained with 1:1 acetic acid/
methanol solution. Experiments were performed in trip-
licate. Zymographic bands, which are indicative of MMP
activity, were quantified by scanning densitometry.
Statistical analyses
The normality of variable distributions was determined
using the Shapiro-Wilk test. Associations between MYC,
FBXW7, and TP53 copy number variation, mRNA levels,
protein expression, clinicopathological features, and cell
invasion and migration capability were analyzed using
the chi-square (χ2) and Mann–Whitney tests. Correl-
ation between expression of the different target mRNAs
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below 0.3 indicated a weak correlation, 0.3-0.7 indicated
a medium correlation, and values above 0.7 indicated a
strong correlation. Data are shown as the median and
interquartile range; p values less than 0.05 were consid-
ered significant.
Results
Gastric tumor specimens showed amplification of MYC
and deletion of FBXW7 and TP53
Three or more copies of MYC were found in 51.5% (17/
33) of gastric tumor cells. In contrast, 45.5% (15/33) and
21.2% (7/33) of gastric tumor cells contained only one
copy of FBXW7 and TP53, respectively.
The association between clinicopathological features
and MYC, FBXW7, and TP53 copy number is summa-
rized in Table 1. One gastric tumor that contained three
copies of TP53 was excluded from the chi-square
analysis. No association was found between copy num-
ber variation of the genes studied and clinicopathologi-
cal features.
MYC mRNA expression was higher in tumors than in
non-neoplastic specimens, whereas FBXW7 and TP53
mRNA expression was lower in tumor specimens
The expression level of MYC mRNA (2.01 ± 1.72 fold
change) in tumor tissue samples was significantly higher
than in non-neoplastic tissue (p = 0.0002), whereas the
expression level of FBXW7 mRNA (0.53 ± 0.40 fold
change) and TP53 mRNA (0.84 ± 0.55 fold change) in
tumor tissue specimens was significantly lower than in
non-neoplastic tissue (p < 0.0001 and p = 0.0011, respect-
ively). We did not find a significant correlation between
MYC, FBXW7, and TP53 mRNA expression (MYC/
FBXW7 mRNA r = −0.3464, p = 0.0562; MYC/TP53
mRNA r = 0.0950, p = 0.6113; FBXW7/TP53 mRNA
r = −0.0745, p = 0.4747). Thus, only a tendency toward
correlation between an increase in MYC mRNA ex-
pression and a decrease in FBXW7 mRNA expression
was detected.
Table 2 summarizes the associations between various
clinicopathological features and the RQ of MYC, FBXW7,
and TP53 mRNA expression in tumor and paired non-
neoplastic specimens. An increase in MYC mRNA level
was associated with the presence of lymph node metasta-
sis (p = 0.016) and GC tumor stage III-IV (p = 0.036). A
significant reduction in FBXW7 mRNA level was also
associated with the presence lymph node metastasis
(p = 0.015) and tumor stage III-IV (p = 0.008).
Nuclear MYC protein staining is associated with
intestinal-type GC
Positive staining for nuclear MYC and p53 was found in
64.5% (20/31) and 19.4% (6/31) of GC samples,respectively (Figure 1). No positivity was found for
FBXW7. Table 1 summarizes the clinicopathological
features and MYC and p53 immunostaining results.
Expression of MYC was more frequent in intestinal-type
than diffuse-type GC (p = 0.007). Furthermore, MYC
immunostaining was associated with increased MYC
mRNA level (p = 0.0022). No association was found
between p53 immunostaining and clinicopathological
characteristics, TP53 copy number, or TP53 mRNA
expression.Comparison of ACP02 and ACP03 cell lines
Both ACP02 and ACP03 cells contained three MYC
copies and only one FBXW7 copy. The number of TP53
copies was undetermined in both cell lines. Compared
with mRNA expression in ACP03 cells, ACP02 cells
expressed a higher level of MYC (1.34-fold) and lower
levels of FBXW7 and TP53 mRNA (0.62- and 0.73-fold,
respectively).
Western blot analyses revealed that MYC expression
was significantly higher in ACP02 cells than ACP03 cells
(p = 0.048). Moreover, FBXW7 expression was significantly
lower in ACP02 cells than ACP03 cells (p = 0.049). How-
ever, there was no significant difference in p53 expression
between the cell lines (p = 0.077) (Figure 2A-B).
Immunofluorescence analysis of both proteins showed
a punctiform pattern of labeling, supporting the Western
blot results showing an increase in MYC and reduction
in FBXW7 expression in ACP02 cells compared with
ACP03 (Figure 2). Matrigel invasion assay results
showed that ACP02 cells were more invasive than
ACP03 cells (p = 0.001). Migration assay results showed
that fewer ACP02 cells migrated compared with ACP03
cells (p = 0.0028) (Figure 2C-D).
Both ACP02 and ACP03 cells presented four gelatinase
activity bands: MMP-9 latent (92 kDa), MMP-9 active
(88 kDa), MMP-2 latent (72 kDa), and MMP-2 active
(66 kDa) (Figure 3). We found no significant differences in
MMP-9 latent (p = 0.9788), MMP-2 active (p = 0.7848),
and MMP-2 latent (p = 0.1678) between ACP02 and
ACP03 cells. However, significant differences were found
between ACP02 and ACP03 cells with respect to MMP-9
active (p = 0.0182).Discussion
In the current study, we observed that MYC mRNA ex-
pression was increased in GC samples compared with
corresponding non-neoplastic samples. In addition, to
our knowledge, this is the first study to report an associ-
ation between increased MYC mRNA expression and
the presence of lymph node metastasis and CG stage
III-IV, reinforcing the idea that MYC deregulation is a
strong factor for malignancy in GC.
Table 2 MYC, FBXW7 and TP53 mRNA expression levels and clinicopathological factors of 33 gastric cancer patients
n (%) MYC p- value FBXW7 p- value TP53 p- value
Median ± IQR Median ± IQR Median ± IQR
Age (y) (mean ± SD)
>50 (65.3 ± 9.1) 19 (57.6%) 2.04 ± 1.35 0.8873 0.55 ± 0.37 0.9247 0.86 ± 0.62 0.7409
≤50 (42.1 ± 8.2) 14 (42.4%) 1.44 ± 4.88 0.53 ± 0.50 0.94 ± 1.65
Gender
Male 15 (45.5%) 2.01 ± 1.01 0.4065 0.53 ± 0.22 0.6353 0.89 ± 0.58 0.8125
Female 18 (54.5%) 1.67 ± 2.03 0.56 ± 0.56 0.87 ± 0.69
Histopathology
Intestinal 22 (66.7%) 2.06 ± 0.99 0.3525 0.53 ± 0.16 0.1391 0.81 ±0.78 0.3311
Diffuse 11 (33.3%) 1.40 ± 2.32 0.77 ±0.74 0.94 ± 0.38
Depth of tumor invasion
T1 6 (18.2%) 0.89 ± 0.47 0.0857 0.88 ± 0.58 0.0678 0.85 ± 0.15 0.7069
T2-T4 27 (81.8%) 2.08 ± 1.42 0.53 ± 0.43 0.91 ± 0.79
Lymph node metastasis
Absent 13 (39.4%) 0.98 ± 1.09 0.0225* 0.68 ± 0.36 0.0238* 0.84 ± 0.44 0.6121
Present 20 (60.6%) 2.10 ± 2.20 0.46 ± 0.38 0.94 ± 0.79
Stage
I-II 18 (54.5%) 1.39 ± 1.23 0.0362* 0.57 ± 0.38 0.0380* 0.83 ± 0.55 0.0892†
III-IV 15 (45.5%) 2.41 ± 2.79 0.34 ± 0.45 0.96 ± 1.19
MYC IHC
Positive 20 (60.6%) 2.18 ± 1.59 0.0022* 0.53 ± 0.32 0.4090 0.81 ± 0.57 0.1372
Negative 13 (39.4%) 0.89 ± 0.85 0.58 ± 0.53 0.99 ± 0.90
p53 IHC
Positive 7 (21.2%) 4.25 ± 6.53 0.0891 0.64 ± 0.68 0.9203 1.06 ± 0.83 0.2937
Negative 26 (78.8%) 2.00 ± 1.44 0.55 ± 0.35 0.87 ± 0.60
*p < 0.05; IQR: interquartile range.
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that MYC mRNA expression deregulation can promote
the development of cancer in transgenic mouse models.
The increase in MYC mRNA level in human cancers
may result from both direct and indirect mechanisms,
which could have several explanations. First, MYC
amplification is the most common mechanism of MYC
deregulation in GC [5]. This mechanism leads to
increased production of oncogenic products in quan-
tities that exceed the transcriptional capacity of a normal
double copy gene. Here, we observed three or more
MYC gene copies in 51.5% of gastric tumors specimens.
Previous studies from our group also showed that MYC
amplification or trisomy of chromosome 8, on which
MYC is located, was present in all GC samples examined
from individuals in Northern Brazil, as well as in GC cell
lines established by our group from tumors of Brazilian
patients [18,22-27]. The presence of MYC amplification
has also been reported in plasma samples from individ-
uals with GC [28]. However, no direct associationbetween MYC copy number variation and mRNA expres-
sion was detected in the present study.
Second, the increase in MYC mRNA expression may
result from consistent recombination between the
immunoglobulin (Ig) locus and the MYC oncogene. This
phenomenon is frequently described in Burkitt’s lymph-
oma and is associated with a longer half-life of MYC
mRNA in affected cells [29]. Previously, our research
group observed MYC insertions in diffuse-type GC
mainly into chromosomes that are mapped to genes of
immunoglobulins (chromosomes 2, 14, and 22) [26].
Thus, chromosomal translocations involving the MYC
locus (8q24) in diffuse-type CG in individuals from
Northern Brazil might also reflect an increase in MYC
mRNA level.
Immunohistochemistry (IHC) analysis revealed that
MYC expression is more frequently found in intestinal-
type GC than diffuse-type GC specimens. These alter-
ations could lead to an abnormal MYC protein that is
not recognized by either of the antibodies used in the
Figure 1 Immunohistochemical analysis of MYC and p53 protein expression in GC. (A) Negative MYC immunostaining in diffuse-type GC;
(B) MYC immune positivity in intestinal-type GC; (C) Positive p53 immunostaining in diffuse-type GC; (D) p53 immune positivity in intestinal-type
GC (magnification × 40).
Figure 2 MYC, FBXW7 and p53 expression, migration and invasion ability in ACP02 and ACP03. (A) Graph show mean ± SD of MYC,
FBXW7 and p53 protein expression in ACP02 and ACP03. These proteins were normalized to the level of beta actin; (B) Representative data of
MYC, FBXW7 and p53 protein expression; (C-D) Graphs show mean ± SD of migration and invasive cells triplicates assay; (E) Representative
results of MYC, FBXW7 and p53 immunofluorescence.
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Figure 3 Representative gelatin zymography analysis of MMP-2 and MMP-9 activity in ACP02 and ACP03. (A) Bands corresponding to
both latent and active forms of MMP-2 and MMP-9 were observed in ACP02 and ACP03. Densitometric analyses are of the bands corresponding
to latent and active forms of MMP-2 (B) and MMP-9 (C).
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between MYC mRNA expression level and MYC staining.
Furthermore, posttranscriptional mechanisms control
MYC stability [6,30]. MYC deregulation has been associ-
ated with loss of FBXW7, a haploinsufficient tumor
suppressor gene. In general, FBXW7 loss may be caused
by loss of heterozygosity (LOH) and mutation [30]. The
loss at 4q, the FBXW7 locus, is a recurring chromosomal
alterations in GC [31,32], and FBXW7 mutations have
been found in 3.7-6% of gastric tumors [12].
In the present study, we observed only one copy of the
FBXW7 gene in 45.16% of the gastric tumors studied.
Interestingly, FBXW7 mRNA expression in GC samples
is markedly decreased in comparison with corresponding
non-neoplastic tissue. In addition, FBXW7 mRNA
expression deregulation was associated with the pres-
ence of lymph node metastasis and GC stage III-IV, as
was also observed with MYC mRNA. These findings
corroborate the work of Yokobori el al. [13], which also
showed an association between reduced FBXW7 mRNA
expression and lymph node metastasis that contributes
to the malignant potential of GC cells and results in
poor prognosis. Moreover, we observed that the expres-
sion of MYC and FBXW7 mRNA tended to be inversely
correlated in the present study.
Several studies showed that MYC inactivation sup-
presses tumors in animals, suggesting that MYC may be
a molecular target in cancer treatment [33-35]. Alterna-
tively, Soucek et al. [36] proposed that FBXW7 might
facilitate “tumor dormancy therapy”. Thus, MYC degrad-
ation by FBXW7 may not only induce a state of tumor
dormancy but could also have an anti-tumor effect.
Normally, MYC accumulation resulting from FBXW7
loss or another mechanism of MYC deregulation induces
p53-dependent apoptosis via MDM2 degradation. The
inactivation of both FBXW7 and p53 promotes MYC
accumulation and inhibits p53-dependent apoptosis viaMDM2 activation, which may in turn induce cell prolif-
eration [37,38].
In this study, we found that 21.2% of the gastric
tumors examined had one copy of the TP53 gene and
also found a substantial decrease in TP53 mRNA level
in GC tissues compared with paired non-neoplastic gas-
tric tissue samples. Loss of p53 function could be caused
primarily by LOH and mutations. TP53 mutations in
somatic cells are observed in about 50% of human
cancers, but the frequency and type of mutation varies
from one tumor to another and can be exchange of
sense, nonsense, deletion, insertion, or splicing muta-
tions [39,40]. In CG, the rate of mutations in this gene is
18-58% [41-43]. Some studies have shown that most
missense mutations in TP53 cause changes in the
conformation of the protein, thereby prolonging its half-
life and leading to accumulation in the nucleus of
neoplastic cells. This accumulation can be detected by
IHC in about 19-29% of GC tumors [44]. Here, we
observed p53 immunostaining in 19.4% (6/31) of GC
samples. This finding was consistent with earlier studies
by our group that described LOH of TP53 and deletion
of 17p as frequent alterations in GC cell lines and
primary gastric tumors from individuals in Northern
Brazil [27,45]. The LOH may be related to the reduction
of TP53 mRNA expression observed in some of our GC
samples. However, no association was found between
this protein, TP53 mRNA level, copy number, or clinico-
pathological features. The lack of association between
MYC, FBXW7, and TP53 copy number variation and
mRNA and protein expression observed in this study
highlights the complex relationship between gene copy
number, mRNA expression, and protein stability.
In our previous cytogenetic study using fluorescence
in situ hybridization (FISH), we described gains in MYC
copies and deletions in TP53 in ACP02 and ACP03
gastric adenocarcinoma cell lines, thus corroborating the
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alterations were observed in the primary tumors from
which these cell lines were established. Since ACP02 and
ACP03 cells present alterations similar to those of
gastric tumors, these cell lines may be useful as tools for
experimental modeling of gastric carcinogenesis and
may enhance understanding of the genetic basis under-
lying GC behavior and treatment and perhaps may
change the landscape of GC.
In the present study, we also observed increased MYC
and reduced FBXW7 mRNA and protein expression in
ACP02 cells compared with ACP03 cells. Furthermore,
ACP02 cells were more invasive than ACP03 cells. On
the other hand, ACP03 cells had a higher migration
capability than ACP02 cells. Thus, despite the ability to
migrate, ACP03 cells probably do not have efficient inva-
sive machinery such as active proteases necessary to
degrade the substrate. These findings are in agreement
with observations in gastric tumors and reinforce the
hypothesis that deregulation of MYC and FBXW7 is
crucial for the invasive ability of GC cells. This result
encouraged us to investigate the MMP-2 and MMP-9
activities of cells using zymography. The MMPs are
synthesized as latent enzymes and later activated via
proteolytic cleavage by themselves or other proteins in
the intracellular space. Both proteases are synthesized
predominantly by stromal cells rather than cancer cells
and both contribute to cancer progression [46]. Our
zymography analysis revealed no significant differences
in the activity of MMP2 between ACP02 and ACP03
cells. Additionally, MMP-9 was more active in ACP02
than ACP03 cells. Studies have shown that high levels of
MMP-2 and/or MMP-9 are significantly correlated with
GC invasion and are associated with poor prognosis
[47,48]. Sampieri et al. [49] showed that MMP-9 expres-
sion is enhanced in GC mucosa compared to non-
neoplastic mucosa and that gelatinase activity differs
significantly between cancerous and normal tissue.
Conclusions
In conclusion, our findings show that FBXW7 and MYC
mRNA levels reflect the potential for aggressive biologic
behavior of gastric tumors and may be used as indicators
of poor prognosis in GC patients. Furthermore, MYC
can be a potential biomarker for use in development of
new targets for GC therapy.
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